Regeneron said total revenues for Q4 2023 rose 1% year over year to $3,434 million, and full-year total revenues rose 8% to $13,117 million. Excluding Ronapreve, revenues for Q4 rose 14%, and full-year revenues rose 12%.

1. 01

   Regeneron said total revenues for Q4 2023 rose 1% year over year to $3,434 million, and full-year total revenues rose 8% to $13,117 million. Excluding Ronapreve, revenues for Q4 rose 14%, and full-year revenues rose 12%.

2. 02

   The company said GAAP diluted earnings per share for Q4 2023 were $10.19 (versus $10.50 a year earlier), and full-year GAAP diluted EPS were $34.77 (versus $38.22). Non-GAAP diluted EPS for Q4 were $11.86, and full-year non-GAAP diluted EPS were $43.79.

3. 03

   The company said combined U.S. net sales of EYLEA HD and EYLEA for Q4 2023 were $1,461 million, down 2% from a year earlier, and full-year combined U.S. net sales were $5,886 million, down 6%. EYLEA HD net sales were $123 million for Q4 and $166 million for the full year.

4. 04

   Regeneron said it recorded $2.215 billion for share repurchases in 2023 as Treasury Stock, and that $1.5 billion remained available under its share repurchase program as of December 31, 2023. The company's GAAP R&D guidance for 2024 is $4.820 to $5.070 billion.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the opening part of the filing body and confirmed exhibits, within a length limit. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.